Genmab A/S (NASDAQ:GMAB) Receives $45.20 Consensus Target Price from Analysts

Shares of Genmab A/S (NASDAQ:GMAB) have been assigned an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $45.20.

A number of equities research analysts have weighed in on GMAB shares. Truist Financial lowered their price objective on Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, September 9th. BMO Capital Markets reiterated an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Wednesday, October 16th. Redburn Atlantic started coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating on the stock. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $31.00 target price on shares of Genmab A/S in a report on Wednesday, September 11th.

Institutional Investors Weigh In On Genmab A/S

Large investors have recently modified their holdings of the business. Legacy Wealth Asset Management LLC raised its position in Genmab A/S by 1.1% in the 3rd quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company’s stock valued at $1,097,000 after buying an additional 471 shares during the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after purchasing an additional 478 shares during the last quarter. Eagle Asset Management Inc. lifted its position in shares of Genmab A/S by 10.0% in the third quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock worth $285,000 after purchasing an additional 1,121 shares in the last quarter. Rhumbline Advisers boosted its holdings in Genmab A/S by 7.1% during the second quarter. Rhumbline Advisers now owns 18,694 shares of the company’s stock worth $470,000 after purchasing an additional 1,236 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in Genmab A/S by 43.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock valued at $113,000 after purchasing an additional 1,413 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB opened at $20.31 on Friday. The business has a 50 day simple moving average of $21.80 and a 200 day simple moving average of $24.78. Genmab A/S has a 52 week low of $19.85 and a 52 week high of $32.88. The stock has a market cap of $13.44 billion, a price-to-earnings ratio of 19.72, a PEG ratio of 0.67 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The firm had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. During the same period in the prior year, the firm earned $0.47 EPS. On average, analysts predict that Genmab A/S will post 1.28 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.